A natural plant compound called tenuifolin significantly reduced atherosclerotic plaque buildup, improved cholesterol levels, and decreased blood vessel inflammation in mice, according to Gram Research analysis of a 2026 preclinical study. The compound appears to work by blocking a cellular pathway called JAK1/STAT1 that drives blood vessel damage. However, this research has not yet been tested in humans, so tenuifolin is not yet a proven treatment for heart disease.
Researchers tested a natural compound called tenuifolin, extracted from a plant called Polygala tenuifolia, to see if it could help prevent atherosclerosis, a dangerous buildup of plaque in blood vessels. Using mice fed a high-fat diet and human cell studies, scientists found that tenuifolin reduced plaque formation, improved cholesterol levels, and reduced inflammation in blood vessels. The compound appears to work by blocking a specific cellular pathway that causes blood vessel damage. While these results are encouraging, the research is still in early stages and has not yet been tested in humans.
Key Statistics
A 2026 preclinical study found that tenuifolin treatment markedly reduced atherosclerotic lesions and improved serum lipid profiles in mice fed a high-fat diet, with the compound confirmed to accumulate in aortic tissue after administration.
In human blood vessel cells exposed to oxidized cholesterol, tenuifolin increased protective endothelial markers CD31 and VE-cadherin while decreasing harmful mesenchymal markers associated with vessel damage and scarring.
Metabolomic analysis in the 2026 study revealed that tenuifolin corrected abnormal metabolic patterns associated with atherosclerosis, suggesting benefits beyond blocking a single cellular pathway.
The Quick Take
- What they studied: Whether a natural plant compound called tenuifolin could prevent or reduce atherosclerosis, the buildup of fatty deposits inside blood vessels that can lead to heart attacks and strokes.
- Who participated: The study used genetically modified mice that are prone to developing atherosclerosis when fed a high-fat diet, plus human blood vessel cells grown in laboratory dishes. No human patients were involved in this research.
- Key finding: Tenuifolin treatment significantly reduced plaque buildup in mouse arteries, improved cholesterol levels, and reduced inflammation and scarring in blood vessel walls compared to untreated mice.
- What it means for you: This research suggests tenuifolin might one day become a new treatment for heart disease, but it is still in very early testing stages. Do not take tenuifolin supplements based on this study alone. Talk to your doctor before trying any new supplements, especially if you have heart disease or take blood thinners.
The Research Details
Scientists created atherosclerosis in mice by feeding them a high-fat diet, which mimics how the disease develops in humans. They then gave some mice tenuifolin while others received no treatment. The researchers measured plaque buildup, cholesterol levels, inflammation markers, and blood vessel damage using multiple laboratory techniques including tissue staining, imaging, and chemical analysis.
To understand how tenuifolin works, the team also studied human blood vessel cells in dishes. They exposed these cells to oxidized cholesterol, a substance that damages blood vessels and contributes to atherosclerosis. They then treated some cells with tenuifolin and measured how it affected the cells’ behavior and the activity of specific proteins involved in vessel damage.
The researchers used advanced computer modeling to predict how tenuifolin might interact with the proteins involved in atherosclerosis. They also used specialized chemical analysis to confirm that tenuifolin actually reached the blood vessels after being given to the mice.
This research approach is important because it combines multiple methods to test whether a compound works and how it works. Testing in both animals and human cells helps researchers understand if results might eventually apply to people. The advanced chemical analysis confirms the compound actually reaches the target tissue, which is crucial for knowing whether it could work as a medicine.
This is a preclinical study, meaning it tests ideas in laboratory and animal models before any human testing. The research uses multiple complementary techniques, which strengthens confidence in the findings. However, results in mice and cells do not always translate to humans. The study has not been tested in people with atherosclerosis, so we cannot yet know if it would be safe or effective in patients. The specific sample size of mice used was not reported in the abstract.
What the Results Show
Tenuifolin treatment produced several important improvements in mice with atherosclerosis. The compound significantly reduced the size of fatty plaques in the arteries, meaning less buildup of dangerous deposits in blood vessels. Mice treated with tenuifolin also showed improved cholesterol profiles, with lower levels of harmful cholesterol and better overall lipid balance.
The compound also reduced inflammation in blood vessels, which is a key driver of atherosclerosis progression. Additionally, tenuifolin decreased scarring and fibrosis in vessel walls, meaning it helped prevent the permanent damage that atherosclerosis causes. Chemical analysis of the aorta, the body’s largest artery, confirmed that tenuifolin actually accumulated in the blood vessel tissue after treatment, proving it reached the target location.
In human blood vessel cells exposed to oxidized cholesterol, tenuifolin prevented harmful changes that normally occur during atherosclerosis. The compound increased protective proteins that keep blood vessels healthy while decreasing proteins associated with vessel damage and scarring. These cellular changes suggest the same protective mechanism works at the microscopic level.
Metabolomic analysis, which measures thousands of chemical compounds in tissues, showed that tenuifolin corrected abnormal metabolic patterns associated with atherosclerosis. This suggests the compound helps restore normal cellular function beyond just blocking one specific pathway. The research identified that tenuifolin works partly by suppressing a protein called STAT1 phosphorylation, which is involved in triggering the harmful changes seen in atherosclerosis.
Previous research has shown that tenuifolin has protective effects in the brain, immune system, and lungs. This study extends that knowledge by demonstrating similar protective effects in blood vessels. The compound’s ability to reduce inflammation and prevent cellular damage aligns with its known mechanisms in other tissues. However, this is the first study specifically examining tenuifolin’s effects on atherosclerosis, so direct comparisons to other atherosclerosis treatments are limited.
This research was conducted entirely in laboratory and animal models, not in humans. Results in mice do not always translate to people due to differences in metabolism and disease progression. The study did not compare tenuifolin to existing atherosclerosis medications, so we cannot determine if it would be better, worse, or equivalent to current treatments. The exact dose and duration of treatment needed for human patients remains unknown. Long-term safety data in animals was not reported. The study focused on one specific mechanism, but atherosclerosis is complex and involves many pathways that tenuifolin might not address.
The Bottom Line
Based on this preclinical research, tenuifolin shows potential as a future atherosclerosis treatment, but it is far too early to recommend it for patients. The evidence is strong in laboratory and animal models but has not been tested in humans. Anyone interested in atherosclerosis prevention should focus on proven strategies: maintaining a healthy diet low in saturated fat, exercising regularly, not smoking, managing stress, and taking medications prescribed by their doctor. Do not take tenuifolin supplements based on this single study.
This research is most relevant to cardiovascular researchers and pharmaceutical companies developing new heart disease treatments. People with atherosclerosis or high risk for heart disease should be aware of this emerging research but should not change their treatment plans based on it. Healthcare providers may find this research interesting for understanding new potential therapies. The general public should understand this represents early-stage research that may or may not lead to a usable treatment.
If tenuifolin proves safe and effective in human clinical trials, it would likely take 5 to 10 years or more before it could become available as a medication. First, researchers must conduct safety studies in humans, then small efficacy trials, then larger trials comparing it to existing treatments. Even if all trials succeed, regulatory approval and manufacturing would add additional time. This timeline assumes the research progresses smoothly, which is not guaranteed.
Frequently Asked Questions
Can I take tenuifolin supplements to prevent heart disease?
Not based on current evidence. This research is preclinical, meaning it has only been tested in animals and cells, not humans. Tenuifolin supplements are not proven safe or effective for heart disease prevention. Consult your doctor before taking any new supplements, especially if you have heart disease or take medications.
How does tenuifolin prevent atherosclerosis?
According to the 2026 research, tenuifolin appears to work by blocking a cellular pathway called JAK1/STAT1 that normally triggers blood vessel damage. This prevents the harmful transformation of blood vessel cells and reduces inflammation and scarring in artery walls.
When will tenuifolin be available as a heart disease treatment?
If development continues successfully, tenuifolin would need to pass human safety trials and efficacy studies before regulatory approval, a process typically taking 5 to 10 years or longer. There is no guarantee this research will lead to an approved medication.
Is tenuifolin better than current atherosclerosis medications?
This study did not compare tenuifolin to existing treatments, so we cannot determine if it would be better, worse, or equivalent. Current medications like statins have decades of proven safety and effectiveness in humans, while tenuifolin has only been tested in animals.
What should I do now to prevent atherosclerosis?
Focus on proven strategies: eat a heart-healthy diet low in saturated fat, exercise at least 150 minutes weekly, avoid smoking, manage stress, and maintain a healthy weight. If you have risk factors, take medications prescribed by your doctor and get regular cholesterol and blood pressure checks.
Want to Apply This Research?
- Users interested in atherosclerosis prevention could track weekly adherence to proven risk reduction strategies: days per week of 30-minute exercise, servings of vegetables consumed daily, and whether they took prescribed heart medications as directed.
- The app could help users implement evidence-based atherosclerosis prevention by setting reminders for daily walks, tracking dietary choices to reduce saturated fat intake, and monitoring medication adherence. Users could log their cholesterol levels when tested and track trends over time.
- Long-term tracking should focus on modifiable risk factors: exercise frequency and duration, diet quality, smoking status, stress levels, and medication compliance. Users should also log periodic cholesterol and blood pressure measurements from their doctor to monitor disease progression or improvement.
This article summarizes preclinical research that has not been tested in humans. Tenuifolin is not an approved medication and should not be used to treat or prevent atherosclerosis or heart disease without consulting a healthcare provider. Results in animal models do not guarantee safety or effectiveness in people. If you have atherosclerosis, heart disease, or cardiovascular risk factors, work with your doctor to develop a treatment plan based on proven therapies. Do not stop taking prescribed medications or change your treatment based on this research. Always consult your healthcare provider before starting any new supplement or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.